Now weaning sits at the center of this dementia and brain health question.

Doctors are weaning dementia patients off certain medications because these drugs are directly worsening their cognitive decline and overall health outcomes. Recent medical research, including a March 2025 systematic review examining relationships between anticholinergic medications and dementia progression, has confirmed that high anticholinergic burden is associated with reduced mobility, increased dementia risk, and poorer outcomes including mortality in older adults who already have cognitive problems. The primary target of this deprescribing effort is anticholinergic medications—a broad class of drugs that block acetylcholine signals in the brain and body. These medications were widely prescribed for decades without fully understanding their cumulative cognitive impact, but today’s evidence is clear: for someone already managing dementia, these drugs are actively harmful.

This shift represents a fundamental change in how geriatricians and neurologists approach medication management in dementia care. Rather than simply adding more medications to address symptoms, doctors are now questioning whether existing medications might be making cognitive problems worse. The deprescribing movement has gained momentum through new clinical guidelines, pharmacist-led interventions, and a growing understanding that sometimes the best medical decision is removing medications that seemed necessary years ago. This article explains which medications are being discontinued, why the science supports this change, what the deprescribing process looks like, and how families and patients can engage in these important conversations with their healthcare providers.

Which Common Medications Are Doctors Removing from Dementia Patients?
The Evidence Behind Why These Medications Harm the Dementia Brain
Clinical Guidelines Now Recommend Minimizing These Medications
How Does the Deprescribing Process Actually Work?
What About the Anti-Dementia Medications Themselves—Should Those Be Stopped Too?
Why Pharmacist-Led Deprescribing Programs Get the Best Results
The Future of Medication Management in Dementia: Deprescribing as Standard Care
Conclusion

Which Common Medications Are Doctors Removing from Dementia Patients?

The medications being most aggressively deprescribed in dementia care are anticholinergic drugs, a class so wide-ranging that many patients don’t realize they’re taking them. These include bladder antimuscarinics (used for overactive bladder), certain antidepressants, antihistamines, and antispasmodics. A notable finding from 2025 stem cell research published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions revealed that antidepressants and bladder antimuscarinics were consistently cytotoxic to neurons—meaning they directly damage brain cells—while antihistamines and antispasmodics did not show the same level of overt cell death. This distinction is crucial because it means not all anticholinergic drugs pose equal risk.

For example, a patient taking an anticholinergic antidepressant for depression and an anticholinergic bladder medication for urinary incontinence is facing cumulative neural damage from both drugs, even though each was prescribed for legitimate reasons. The cumulative effect, called “anticholinergic burden,” is what doctors now focus on. A patient taking one low-dose anticholinergic medication might manage fine, but the same patient on multiple drugs with anticholinergic properties—a blood pressure medication here, an antihistamine there, a bladder drug elsewhere—experiences a compounding effect on brain function. This is particularly dangerous in dementia because the brain is already losing neurons and cognitive reserve. The distinction between stopping medication abruptly and tapering doses is also emerging as critical; research on deprescribing approaches shows that gradual dose reduction is far more acceptable to patients and safer than sudden discontinuation, which can cause rebound symptoms or dangerous medical events.

Which Common Medications Are Doctors Removing from Dementia Patients?

The Evidence Behind Why These Medications Harm the Dementia Brain

The scientific case for removing anticholinergic medications from dementia patients rests on multiple lines of evidence gathered in 2024-2025. A systematic review published in the British Journal of Clinical Pharmacology examined anticholinergic deprescribing in hospitalized older adults and found strong associations between high anticholinergic burden and reduced mobility, increased dementia risk, and poor clinical outcomes. The March 2025 study synthesized findings across cognitive decline, dementia development, and long-term outcomes in patients with existing dementia, making a compelling case that these medications accelerate the disease process itself. The mechanism is now clearer than ever.

Anticholinergic drugs work by blocking acetylcholine, a neurotransmitter essential to memory formation, attention, and executive function. In a healthy brain, blocking some acetylcholine might cause minor cognitive side effects; in a dementia brain already starved for acetylcholine, the impact is severe. Interestingly, the evidence also suggests that cholinesterase inhibitor medications (donepezil, rivastigmine) work by increasing acetylcholine levels—making it particularly counterproductive to simultaneously give patients drugs that lower it. However, a crucial caveat: the evidence showing harm is strongest for anticholinergic medications used for non-essential purposes (like overactive bladder), but weaker for certain medications where stopping them creates other serious problems (like antipsychotics prescribed for behavioral symptoms, where abrupt discontinuation can be dangerous).

Major medical organizations have formally shifted their recommendations. The National Institute for Health and Care Excellence (NICE) published dementia guidelines in 2021 recommending that clinicians minimize use of medicines with increased anticholinergic burden and actively address reversible causes of cognitive impairment caused by anticholinergic medications. These guidelines represent a complete reversal from prior decades when anticholinergic drugs were prescribed liberally with little concern for cognitive effects. The 2025 “Deprescribing for People with Dementia: A Roadmap” published in Drugs & Aging provides comprehensive guidance on how to safely reduce and discontinue these medications while maintaining patient safety. What makes these guidelines practical rather than just theoretical is that they acknowledge real barriers to deprescribing.

Bladder antimuscarinics, for instance, are deeply entrenched in dementia care—prescribed to manage urinary incontinence, a major quality-of-life issue. The guideline recommends dose tapering rather than abrupt cessation because some patients will experience return of incontinence symptoms, and some may refuse the switch. The guidelines also emphasize that deprescribing decisions should involve shared decision-making between doctors, patients, and families, weighing the cognitive benefits of stopping the drug against the practical consequences of returning symptoms. A patient with severe urinary incontinence who is already incontinent may rationally decide that dementia progression matters more than bladder control; another patient might prioritize continence. There is no one-size-fits-all answer.

Clinical Guidelines Now Recommend Minimizing These Medications

How Does the Deprescribing Process Actually Work?

Deprescribing isn’t simply telling a patient to stop their medication. The evidence-based approach involves several steps: first, determining the patient’s and family’s treatment goals; second, systematically reviewing all medications to identify which ones carry anticholinergic burden and which ones are least essential; third, discussing the benefits and harms of continuing versus stopping each medication; and fourth, establishing a tapering schedule that avoids sudden withdrawal. The shared decision-making model used in modern deprescribing requires that everyone involved—the patient (if cognitively able), the family, and the care team—understands that there are tradeoffs.

For example, a 75-year-old with moderate Alzheimer’s disease who is taking a tricyclic antidepressant for depression and an anticholinergic bladder medication for incontinence might benefit from switching to a newer antidepressant with no anticholinergic properties and exploring non-medication incontinence management. However, if that patient is also taking a low dose of an anticholinergic antihistamine for seasonal allergies, stopping it involves almost no downside. The deprescribing process prioritizes removing medications with the worst cognitive impact and the least essential purposes first. Pharmacist-led interventions have emerged as the most effective implementation method; hospital-based programs with dedicated pharmacists to review medications, recommend deprescribing, and monitor outcomes show the highest success rates and better adherence than physician-only approaches.

What About the Anti-Dementia Medications Themselves—Should Those Be Stopped Too?

This is where the deprescribing conversation gets more complex. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine are anti-dementia medications prescribed to slow cognitive decline, and the evidence for discontinuing them is far weaker than the evidence for removing anticholinergics. A Cochrane review and meta-analysis on deprescribing cholinesterase inhibitors found that discontinuing these drugs may result in worse cognitive, neuropsychiatric, and functional status, though the evidence is of low to very low certainty. Doctors are not rushing to stop these medications. In fact, the opposite is true: international guidelines, including 2025 Korean clinical consensus, strongly recommend cholinesterase inhibitors for Alzheimer’s disease and Lewy body dementia, and strongly recommend memantine for moderate-to-severe Alzheimer’s disease.

A November 2024 study in JAMA Network Open examined what happens when patients start memantine and their cholinesterase inhibitor is discontinued (often done due to cost or side effects). The finding was reassuring: discontinuing the cholinesterase inhibitor when starting memantine was not associated with increased risk of long-term care institutionalization and actually showed lower risk of fall-related injuries. This does not mean cholinesterase inhibitors should be routinely stopped, but rather that if side effects or cost require discontinuation, memantine alone provides some protection. The key distinction is that anti-dementia medications work to preserve remaining brain function, whereas anticholinergic medications actively damage it. Deprescribing anticholinergics makes room for patients to benefit more fully from the medications they need.

What About the Anti-Dementia Medications Themselves—Should Those Be Stopped Too?

Why Pharmacist-Led Deprescribing Programs Get the Best Results

When deprescribing is led by nurses or doctors alone, medication reviews often focus narrowly on the primary indication for each drug. A pharmacist’s role is different: they conduct comprehensive medication reviews, understand drug interactions and cumulative effects, and can identify anticholinergic burden that a prescriber focused on one condition might miss. Research on pharmacist-driven deprescribing to reduce anticholinergic burden in veterans with dementia found that hospital-based interventions led by pharmacists were not only acceptable to patients and families but also achieved the best clinical outcomes and highest medication adherence.

The pharmacist approach involves taking time to educate patients and caregivers about why a medication is being stopped, what symptoms might temporarily return, and how long tapering will take. This relationship-building and patient education are often missing when a doctor simply removes a medication from a prescription list. For families caring for someone with dementia, having a pharmacist explain that stopping a bladder medication might temporarily increase incontinence but will improve cognition gives them agency and realistic expectations rather than confusion. Pharmacist-led programs also monitor deprescribing outcomes—tracking cognitive changes, falls, hospitalizations, and quality of life—making deprescribing an evidence-based clinical intervention rather than just guesswork.

The Future of Medication Management in Dementia: Deprescribing as Standard Care

The deprescribing movement in dementia care represents a maturation of medical understanding. For decades, the model was “add more medications to fix problems,” but that model accumulated toxicity, particularly in older brains. The emerging model is “use minimal effective medication and ensure every drug is earning its place.” This shift will likely accelerate as the evidence base grows and healthcare systems adopt pharmacist-led deprescribing programs as standard practice rather than specialty interventions.

Looking forward, the challenge will be ensuring equitable access to deprescribing expertise. Pharmacist-led programs work best, but not all healthcare settings have the resources to implement them. Families caring for loved ones with dementia should advocate for comprehensive medication reviews, ask about anticholinergic burden specifically, and request shared decision-making conversations about deprescribing. The evidence is now strong enough that deprescribing is no longer experimental or marginal—it is emerging as a core component of dementia care that extends quality of life and extends cognitive function during the time patients have remaining.

Conclusion

Doctors are weaning dementia patients off anticholinergic medications because recent research definitively shows these drugs harm the dementia brain through multiple mechanisms: they block acetylcholine, a neurotransmitter essential to memory and cognition; they are cytotoxic to brain cells; and they accelerate cognitive decline and worsen outcomes including mortality. The medications most commonly deprescribed include bladder antimuscarinics, certain antidepressants, and other anticholinergic drugs prescribed for non-critical purposes. Major clinical guidelines from NICE and international consensus now recommend minimizing these medications, and pharmacist-led deprescribing programs show the highest success rates.

If you are caring for someone with dementia, ask their doctor about their anticholinergic burden, request a comprehensive medication review, and open a conversation about deprescribing. Deprescribing is not about using no medications—anti-dementia drugs remain important—but about removing medications that are actively making cognitive decline worse. The goal is to give the brain the best possible chance by eliminating substances that accelerate its decline, allowing patients and families to focus on living well during the time that remains.